Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 619

1.

Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.

Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M.

Nat Biotechnol. 2020 Feb 10. doi: 10.1038/s41587-019-0404-8. [Epub ahead of print]

PMID:
32042168
2.

Consecutive ultrafiltration and silica adsorption for recovery of extracellular antibiotic resistance genes from an urban river.

Liu M, Hata A, Katayama H, Kasuga I.

Environ Pollut. 2020 Jan 23;260:114062. doi: 10.1016/j.envpol.2020.114062. [Epub ahead of print]

PMID:
32041028
3.

Resistance looms for KRASG12C inhibitors.

Hata AN, Shaw AT.

Nat Med. 2020 Feb;26(2):169-170. doi: 10.1038/s41591-020-0765-z. No abstract available.

PMID:
32020086
4.

Effect of aromatherapy massage on quality of sleep in the palliative care ward: a randomized controlled trial.

Kawabata N, Hata A, Aoki T.

J Pain Symptom Manage. 2020 Jan 22. pii: S0885-3924(20)30047-6. doi: 10.1016/j.jpainsymman.2020.01.003. [Epub ahead of print]

PMID:
31981597
5.

Breastfeeding promotes egg white sensitization in early infancy.

Nakano T, Ochiai S, Suzuki S, Yamaide F, Morita Y, Inoue Y, Arima T, Kojima H, Suzuki H, Nagai K, Morishita N, Hata A, Shozu M, Suzuki Y, Taniguchi M, Takemori T, Kohno Y, Shimojo N.

Pediatr Allergy Immunol. 2020 Jan 11. doi: 10.1111/pai.13208. [Epub ahead of print] No abstract available.

PMID:
31925979
6.

Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.

Klempner SJ, Hata AN.

Cancer Discov. 2020 Jan;10(1):20-22. doi: 10.1158/2159-8290.CD-19-1255.

PMID:
31919120
7.

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Floros KV, Hata AN, Faber AC.

Cancer Res. 2020 Jan 1;80(1):25-26. doi: 10.1158/0008-5472.CAN-19-3405.

PMID:
31900282
8.

Associations of dietary diversity with allergic diseases in Japanese workers: a cross-sectional study.

Nakamoto M, Omine M, Yun Y, Shuto E, Nakamoto A, Hata A, Aki N, Shikama Y, Bando Y, Ichihara T, Minamigawa T, Tamura A, Kuwamura Y, Funaki M, Sakai T.

Asia Pac J Clin Nutr. 2019;28(4):857-869. doi: 10.6133/apjcn.201912_28(4).0023.

9.

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S.

Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6.

10.

Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.

Klempner SJ, Hata AN.

J Thorac Oncol. 2019 Nov;14(11):1875-1877. doi: 10.1016/j.jtho.2019.07.014. No abstract available.

PMID:
31668312
11.

Deciphering the role of eosinophils in solid organ transplantation.

Onyema OO, Guo Y, Hata A, Kreisel D, Gelman AE, Jacobsen EA, Krupnick AS.

Am J Transplant. 2019 Oct 24. doi: 10.1111/ajt.15660. [Epub ahead of print] Review.

PMID:
31647606
12.

Successful Conservative Treatment of Mycotic Pulmonary Artery Aneurysms Caused by MRSA Bacteremia.

Iki Y, Hata A, Fukuyama M, Yoshioka T, Watanabe K, Asari S, Hata D.

Pediatrics. 2019 Nov;144(5). pii: e20190672. doi: 10.1542/peds.2019-0672. Epub 2019 Oct 17.

PMID:
31624217
13.

Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.

Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, Asano Y, Nakamura A, Nambu T, Hata A, Ishii T, Sameshima T, Debori Y, Miyamoto M, Klein MG, Tjhen R, Sang BC, Levin I, Lane SW, Snell GP, Li K, Kefala G, Hoffman ID, Ding SC, Cary DR, Mizojiri R.

ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. doi: 10.1021/acsmedchemlett.9b00400. eCollection 2019 Oct 10.

PMID:
31620240
14.

Reference values of hematological and blood biochemical parameters for the Noma horse.

Ono T, Yamada Y, Hata A, Shimokawa Miyama T, Shibano K, Iwata E, Ohzawa E, Kitagawa H.

J Equine Sci. 2019 Sep;30(3):69-73. doi: 10.1294/jes.30.69. Epub 2019 Oct 2.

15.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV.

J Thorac Oncol. 2019 Oct;14(10):e226-e228. doi: 10.1016/j.jtho.2019.05.046. No abstract available.

PMID:
31558234
16.

A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y.

Cancer Manag Res. 2019 Jul 29;11:7135-7140. doi: 10.2147/CMAR.S208224. eCollection 2019.

17.

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.

Niu J, Sun Y, Chen B, Zheng B, Jarugumilli GK, Walker SR, Hata AN, Mino-Kenudson M, Frank DA, Wu X.

Nature. 2019 Sep;573(7772):139-143. doi: 10.1038/s41586-019-1511-x. Epub 2019 Aug 28.

PMID:
31462771
18.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ.

Cancer Discov. 2019 Oct;9(10):1372-1387. doi: 10.1158/2159-8290.CD-19-0582. Epub 2019 Aug 15.

PMID:
31416802
19.

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T.

Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z.

20.

Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis.

Komatsu-Fujii T, Otsuka A, Ishida Y, Kaku Y, Yamashita C, Hata A, Kataoka T, Honda T, Kabashima K.

Eur J Dermatol. 2019 Jun 1;29(3):326-327. doi: 10.1684/ejd.2019.3547. No abstract available.

PMID:
31389791
21.

Metabolism of 3-[5'-deoxy-5'-(dimethylarsinoyl)-β-ribofuranosyloxy]-2-hydroxypropylene glycol in an artificial digestive system.

Hata A, Hasegawa M, Yamauchi T, Otomo Y, Miura M, Yamanaka K, Yamano Y, Fujitani N, Endo G.

Heliyon. 2019 Jul 19;5(7):e02079. doi: 10.1016/j.heliyon.2019.e02079. eCollection 2019 Jul.

22.

Correction to: Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease.

Thiha K, Mashimo Y, Suzuki H, Hamada H, Hata A, Hara T, Tanaka T, Ito K, Onouchi Y; Japan Kawasaki Disease Genome Consortium.

J Hum Genet. 2019 Oct;64(10):1049. doi: 10.1038/s10038-019-0645-x.

PMID:
31366996
23.

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.

Dagogo-Jack I, Rooney M, Lin JJ, Nagy RJ, Yeap BY, Hubbeling H, Chin E, Ackil J, Farago AF, Hata AN, Lennerz JK, Gainor JF, Lanman RB, Shaw AT.

Clin Cancer Res. 2019 Nov 15;25(22):6662-6670. doi: 10.1158/1078-0432.CCR-19-1436. Epub 2019 Jul 29.

PMID:
31358542
24.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.

Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN.

Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19.

25.

A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.

Hata A, Nakajima T, Matsusaka K, Fukuyo M, Morimoto J, Yamamoto T, Sakairi Y, Rahmutulla B, Ota S, Wada H, Suzuki H, Matsubara H, Yoshino I, Kaneda A.

Int J Cancer. 2020 Jan 15;146(2):388-399. doi: 10.1002/ijc.32532. Epub 2019 Jul 8.

PMID:
31241180
26.

Application of deep learning (3-dimensional convolutional neural network) for the prediction of pathological invasiveness in lung adenocarcinoma: A preliminary study.

Yanagawa M, Niioka H, Hata A, Kikuchi N, Honda O, Kurakami H, Morii E, Noguchi M, Watanabe Y, Miyake J, Tomiyama N.

Medicine (Baltimore). 2019 Jun;98(25):e16119. doi: 10.1097/MD.0000000000016119.

27.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.

Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H.

Cell Rep. 2019 Jun 18;27(12):3422-3432.e4. doi: 10.1016/j.celrep.2019.05.058.

28.

Handheld flow meter improves COPD detectability regardless of using a conventional questionnaire: A split-sample validation study.

Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A.

Respirology. 2020 Feb;25(2):191-197. doi: 10.1111/resp.13602. Epub 2019 Jun 12.

PMID:
31188538
29.

Ultra-low-dose chest computed tomography for interstitial lung disease using model-based iterative reconstruction with or without the lung setting.

Hata A, Yanagawa M, Honda O, Miyata T, Tomiyama N.

Medicine (Baltimore). 2019 May;98(22):e15936. doi: 10.1097/MD.0000000000015936.

30.

Maslinic acid derived from olive fruit in combination with resistance training improves muscle mass and mobility functions in the elderly.

Nagai N, Yagyu S, Hata A, Nirengi S, Kotani K, Moritani T, Sakane N.

J Clin Biochem Nutr. 2019 May;64(3):224-230. doi: 10.3164/jcbn.18-104. Epub 2019 Mar 7.

31.

Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Grassberger C, McClatchy D 3rd, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H.

Cancer Res. 2019 Jul 15;79(14):3776-3788. doi: 10.1158/0008-5472.CAN-18-3652. Epub 2019 May 21.

PMID:
31113818
32.

Chronological changes of skin eruptions in an infantile case of annular pustular psoriasis.

Hata A, Egawa G, Nomura T, Kabashima K.

J Dermatol. 2019 Oct;46(10):e372-e373. doi: 10.1111/1346-8138.14929. Epub 2019 May 20. No abstract available.

PMID:
31106884
33.

Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid.

Irie K, Nanjo S, Hata A, Yamasaki Y, Okada Y, Katakami N, Fukushima S.

Bioanalysis. 2019 May;11(9):847-854. doi: 10.4155/bio-2018-0292. Epub 2019 May 14.

PMID:
31084202
34.

Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences.

Masaki S, Ikeda S, Hata A, Shiozawa Y, Kon A, Ogawa S, Suzuki K, Hakuno F, Takahashi SI, Kataoka N.

Front Genet. 2019 Apr 16;10:338. doi: 10.3389/fgene.2019.00338. eCollection 2019.

35.

Molecular cytogenetic characterization of repetitive sequences comprising centromeric heterochromatin in three Anseriformes species.

Uno Y, Nishida C, Hata A, Ishishita S, Matsuda Y.

PLoS One. 2019 Mar 26;14(3):e0214028. doi: 10.1371/journal.pone.0214028. eCollection 2019.

36.

Inequality within a community at the neighborhood level and the incidence of mood disorders in Japan: a multilevel analysis.

Fujita M, Nagashima K, Takahashi S, Hata A.

Soc Psychiatry Psychiatr Epidemiol. 2019 Sep;54(9):1125-1131. doi: 10.1007/s00127-019-01687-w. Epub 2019 Mar 22.

PMID:
30903241
37.

Deregulation of Drosha in the pathogenesis of hereditary hemorrhagic telangiectasia.

Hata A, Lagna G.

Curr Opin Hematol. 2019 May;26(3):161-169. doi: 10.1097/MOH.0000000000000493.

38.

Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease.

Thiha K, Mashimo Y, Suzuki H, Hamada H, Hata A, Hara T, Tanaka T, Ito K, Onouchi Y; Japan Kawasaki Disease Genome Consortium.

J Hum Genet. 2019 Jun;64(6):511-519. doi: 10.1038/s10038-019-0588-2. Epub 2019 Mar 11. Erratum in: J Hum Genet. 2019 Oct;64(10):1049.

PMID:
30853710
39.

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.

Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators.

Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Erratum in: Lancet. 2019 Mar 30;393(10178):1298. Lancet. 2019 Apr 13;393(10180):1504.

PMID:
30853151
40.

Association between blood manganese level during pregnancy and birth size: The Japan environment and children's study (JECS).

Yamamoto M, Sakurai K, Eguchi A, Yamazaki S, Nakayama SF, Isobe T, Takeuchi A, Sato T, Hata A, Mori C, Nitta H; Japan Environment and Children's Study Group:.

Environ Res. 2019 May;172:117-126. doi: 10.1016/j.envres.2019.02.007. Epub 2019 Feb 8.

41.

Precise Anatomical Sublobar Resection Using a 3D Medical Image Analyzer and Fluorescence-Guided Surgery With Transbronchial Instillation of Indocyanine Green.

Sekine Y, Itoh T, Toyoda T, Kaiho T, Koh E, Kamata T, Hoshino H, Hata A.

Semin Thorac Cardiovasc Surg. 2019 Autumn;31(3):595-602. doi: 10.1053/j.semtcvs.2019.01.004. Epub 2019 Jan 5.

PMID:
30616007
42.
43.

Volumetric analysis of the thymic epithelial tumors: correlation of tumor volume with the WHO classification and Masaoka staging.

Sato Y, Yanagawa M, Hata A, Enchi Y, Kikuchi N, Honda O, Nakanishi K, Tomiyama N.

J Thorac Dis. 2018 Oct;10(10):5822-5832. doi: 10.21037/jtd.2018.09.133. Erratum in: J Thorac Dis. 2019 May;11(5):E79.

44.

Soy product and isoflavone intake associations with allergic diseases in Japanese workers: rhinitis, dermatitis and asthma.

Nakamoto M, Shuto E, Nakamoto A, Hata A, Aki N, Shikama Y, Bando Y, Ichihara T, Minagawa T, Tamura A, Kuwamura Y, Funaki M, Sakai T.

Asia Pac J Clin Nutr. 2018;27(6):1277-1285. doi: 10.6133/apjcn.201811_27(6).0015.

45.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

46.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.

Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, Myers DT, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan J, Stein GT, Murchie E, Zarrinkar PP, Janes MR, Li LS, Liu Y, Hata AN, Benes CH.

Clin Cancer Res. 2019 Jan 15;25(2):796-807. doi: 10.1158/1078-0432.CCR-18-0368. Epub 2018 Oct 16.

47.

Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan.

Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T.

Int J Urol. 2019 Jan;26(1):96-101. doi: 10.1111/iju.13817. Epub 2018 Oct 11.

48.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

49.

Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells.

Vattulainen-Collanus S, Southwood M, Yang XD, Moore S, Ghatpande P, Morrell NW, Lagna G, Hata A.

Commun Biol. 2018 Sep 24;1:149. doi: 10.1038/s42003-018-0152-1. eCollection 2018.

50.

Differences in apoptotic signaling and toxicity between dimethylmonothioarsinic acid (DMMTAV) and its active metabolite, dimethylarsinous acid (DMAIII), in HepaRG cells: Possibility of apoptosis cascade based on diversity of active metabolites of DMMTAV.

Shimoda Y, Kato K, Asami S, Kurita M, Kurosawa H, Toriyama M, Miura M, Hata A, Endo Y, Endo G, An Y, Yamanaka K.

J Trace Elem Med Biol. 2018 Dec;50:188-197. doi: 10.1016/j.jtemb.2018.07.003. Epub 2018 Jul 10.

PMID:
30262279

Supplemental Content

Support Center